Fort Worth, Texas (Vocus) April 6, 2009
Proven effective in the management of the feline herpes virus (FHV-1), Enisyl-F is now available as an oral supplement in the form of a treat for cats and kittens.
Manufactured by Vétoquinol USA, Enisyl-F Lysine Treats are a safe and effective nutritional supplement that helps lessen the severity of FHV-1 symptoms and the frequency of flare ups. Enisyl-F contains L-lysine, an essential amino acid that can safely be given to your cat every day, for as long as required.
The treats are a pet owner-friendly way to deliver supplemental lysine to cats or kittens. Highly palatable, Enisyl-F Lysine Treats help boost acceptance from felines, leading to enhanced compliance and a better outcome. The treats can be given as routine administration after treatment with Enisyl-F paste, or Viralys gel or powder, during active flare-ups.
When administered to cats infected with FHV-1, L-lysine has been shown to be effective in lessening the severity of symptoms and reducing viral shedding (or transmission) despite stress factors associated with the reactivation of FHV-1.
Feline herpes virus, one of the most common causes of respiratory infections and eye problems in cats, can be transmitted from cat to cat through discharge from the nose, eyes or mouth and also through litter boxes, water dishes and food. The most common symptoms of FHV-1 in kittens are sneezing and nasal discharge, along with an eye infection and ocular discharge, and in cats, the most common symptoms are chronic eye infections or recurrent corneal ulcers. FHV-1 affects cats only and cannot be passed on to humans or to other species of animals.
Vétoquinol USA is owned by Vétoquinol S.A., a family-owned animal health products company founded in 1933 in Lure, France. Vétoquinol, which celebrated its 75th anniversary in 2008, is an independent veterinary pharmaceutical laboratory dedicated exclusively to both the companion animal and livestock markets. The company is the 11th largest laboratory in the world, and nearly 80 percent of its revenues come from outside France. Vétoquinol engages in the research and development, production and marketing of medical and dietary products. Vétoquinol has positioned itself in the curative sector, and has developed expertise in three major therapeutic fields: anti-infectives, pain management and anti-inflammatories, and cardiology and nephrology. The Group currently distributes its products in one hundred countries throughout Europe, North America and Asia, with subsidiaries in 22 different countries and a network of 140 distributor partners. The Company has more than 1,400 employees worldwide.